The relationship between metabolism reprogramming and neuroblastoma (NB) is largely unknown. In this study, one RNA‐sequence data set (n = 153) was used as discovery cohort and two microarray data sets (n = 498 and n = 223) were used as validation cohorts. Differentially expressed metabolic genes were identified by comparing stage 4s and stage 4 NBs. Twelve metabolic genes were selected by LASSO regression analysis and integrated into the prognostic signature. The metabolic gene signature successfully stratifies NB patients into two risk groups and performs well in predicting survival of NB patients. The prognostic value of the metabolic gene signature is also independent with other clinical risk factors. Nine metabolism‐related long non‐coding RNAs (lncRNAs) were also identified and integrated into the metabolism‐related lncRNA signature. The lncRNA signature also performs well in predicting survival of NB patients. These results suggest that the metabolic signatures have the potential to be used for risk stratification of NB. Gene set enrichment analysis (GSEA) reveals that multiple metabolic processes (including oxidative phosphorylation and tricarboxylic acid cycle, both of which are emerging targets for cancer therapy) are enriched in the high‐risk NB group, and no metabolic process is enriched in the low‐risk NB group. This result indicates that metabolism reprogramming is associated with the progression of NB and targeting certain metabolic pathways might be a promising therapy for NB.

中文翻译：

---

RNA序列和微阵列数据的组合分析揭示了神经母细胞瘤基于代谢的有效预后标志。

代谢重编程与神经母细胞瘤（NB）之间的关系很大程度上未知。在这项研究中，一个RNA序列数据集（n = 153）被用作发现队列，而两个微阵列数据集（n = 498和n = 223）被用作验证队列。通过比较阶段4s和阶段4 NBs鉴定出差异表达的代谢基因。通过LASSO回归分析选择了12个代谢基因，并将其整合到预后标记中。代谢基因签名成功地将NB患者分为两个风险组，并且在预测NB患者的生存方面表现良好。代谢基因签名的预后价值也与其他临床危险因素无关。还鉴定了九种与代谢有关的长非编码RNA（lncRNA），并将其整合到与代谢有关的lncRNA标记中。lncRNA标记在预测NB患者的生存中也表现良好。这些结果表明，新陈代谢的特征有潜力用于NB的风险分层。基因组富集分析（GSEA）显示，高危NB组富含多种代谢过程（包括氧化磷酸化和三羧酸循环，这两个都是癌症治疗的新兴目标），而低危NB组则没有代谢过程风险NB组。该结果表明代谢重编程与NB的进展有关，并且靶向某些代谢途径可能是NB的有前途的疗法。基因组富集分析（GSEA）显示，高危NB组富含多种代谢过程（包括氧化磷酸化和三羧酸循环，这两个都是癌症治疗的新兴目标），而低危NB组则没有代谢过程风险NB组。该结果表明代谢重编程与NB的进展有关，并且靶向某些代谢途径可能是NB的有前途的疗法。基因组富集分析（GSEA）显示，高危NB组富含多种代谢过程（包括氧化磷酸化和三羧酸循环，这两个都是癌症治疗的新兴目标），而低危NB组则没有代谢过程风险NB组。该结果表明代谢重编程与NB的进展有关，并且靶向某些代谢途径可能是NB的有前途的疗法。